Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip Scheinberg

Showing results (71-80 of 130) with videos related to

Pageof 13
Sort By:
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 20, 2021
Thromboembolic and bleeding events in intensive care unit patients with COVID-19: results from a Brazilian tertiary hospitalAntonio Adolfo Guerra Soares Brandão, Cleyton Zanardo de Oliveira, Salomon Ordinola Rojas, et al.
Blood Advances|January 8, 2025
Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studiesAntonio M Risitano, Carlos de Castro, Bing Han, et al.
The Lancet. Haematology|February 9, 2024
Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm studyPhillip Scheinberg, Carlo Finelli, Efreen H Montaňo-Figueroa, et al.
Blood|August 25, 2010
Th17 immune responses contribute to the pathophysiology of aplastic anemiaRegis Peffault de Latour, Valeria Visconte, Tomoiku Takaku, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2014
Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuriaJeremy Pantin, Xin Tian, Nancy Geller, et al.
Blood|September 25, 2009
The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donorPhillip Scheinberg, Jan J Melenhorst, Jason M Brenchley, et al.
Blood Advances|April 3, 2019
Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumabCatherine Lai, Vishal Ranpura, Colin Wu, et al.
Blood|December 19, 2013
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drugRonan Desmond, Danielle M Townsley, Bogdan Dumitriu, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2025
Comparative Efficacy and Safety of Daratumumab-Integrated Quadruple Therapy Versus Triple Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-AnalysisKleuber Arias Meireles Martins, Leonardo Januário Campos Cardoso, Filipe Melo Ribeiro, et al.
The New England Journal of Medicine|July 6, 2012
Eltrombopag and improved hematopoiesis in refractory aplastic anemiaMatthew J Olnes, Phillip Scheinberg, Katherine R Calvo, et al.
Pageof 13

Showing results (71-80 of 130) with videos related to

Sort By:
Pageof 13
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 20, 2021
Thromboembolic and bleeding events in intensive care unit patients with COVID-19: results from a Brazilian tertiary hospitalAntonio Adolfo Guerra Soares Brandão, Cleyton Zanardo de Oliveira, Salomon Ordinola Rojas, et al.
Blood Advances|January 8, 2025
Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studiesAntonio M Risitano, Carlos de Castro, Bing Han, et al.
The Lancet. Haematology|February 9, 2024
Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm studyPhillip Scheinberg, Carlo Finelli, Efreen H Montaňo-Figueroa, et al.
Blood|August 25, 2010
Th17 immune responses contribute to the pathophysiology of aplastic anemiaRegis Peffault de Latour, Valeria Visconte, Tomoiku Takaku, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2014
Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuriaJeremy Pantin, Xin Tian, Nancy Geller, et al.
Blood|September 25, 2009
The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donorPhillip Scheinberg, Jan J Melenhorst, Jason M Brenchley, et al.
Blood Advances|April 3, 2019
Long-term outcomes in myelodysplastic syndrome patients treated with alemtuzumabCatherine Lai, Vishal Ranpura, Colin Wu, et al.
Blood|December 19, 2013
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drugRonan Desmond, Danielle M Townsley, Bogdan Dumitriu, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2025
Comparative Efficacy and Safety of Daratumumab-Integrated Quadruple Therapy Versus Triple Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-AnalysisKleuber Arias Meireles Martins, Leonardo Januário Campos Cardoso, Filipe Melo Ribeiro, et al.
The New England Journal of Medicine|July 6, 2012
Eltrombopag and improved hematopoiesis in refractory aplastic anemiaMatthew J Olnes, Phillip Scheinberg, Katherine R Calvo, et al.
Pageof 13